Adlarity is a drug owned by Corium Llc. It is protected by 11 US drug patents filed from 2022 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 11, 2038. Details of Adlarity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US12161767 | Systems and methods for long term transdermal administration |
Dec, 2036
(11 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10966936 | Systems comprising a composite backing and methods for long term transdermal administration |
Aug, 2038
(13 years from now) | Active |
| US10835499 | Systems and methods for long term transdermal administration |
May, 2038
(13 years from now) | Active |
| US11648214 | Systems and methods for long term transdermal administration |
Sep, 2037
(12 years from now) | Active |
| US10307379 | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | Active |
| US10300025 | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | Active |
| US9993466 | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | Active |
| US11103463 | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(12 years from now) | Active |
| US10016372 | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(12 years from now) | Active |
| US11679086 | Systems comprising a composite backing and methods for long term transdermal administration |
May, 2037
(12 years from now) | Active |
| US12168075 | Systems comprising a composite backing and methods for long term transdermal administration |
Dec, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adlarity's patents.
Latest Legal Activities on Adlarity's Patents
Given below is the list of recent legal activities going on the following patents of Adlarity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10835499 |
| Electronic Review Critical | 26 Jun, 2023 | US11679086 |
| Electronic Review Critical | 21 Jun, 2023 | US11679086 |
| Email Notification Critical | 21 Jun, 2023 | US11679086 |
| Patent eGrant Notification | 20 Jun, 2023 | US11679086 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Jun, 2023 | US11679086 |
| Recordation of Patent eGrant | 20 Jun, 2023 | US11679086 |
| Mail Patent eGrant Notification | 20 Jun, 2023 | US11679086 |
| Recordation of Patent Grant Mailed Critical | 20 Jun, 2023 | US11679086 |
| Electronic Review Critical | 01 Jun, 2023 | US11679086 |
FDA has granted several exclusivities to Adlarity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Adlarity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Adlarity.
Exclusivity Information
Adlarity holds 1 exclusivities. All of its exclusivities have expired in 2025. Details of Adlarity's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2025 |
US patents provide insights into the exclusivity only within the United States, but Adlarity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adlarity's family patents as well as insights into ongoing legal events on those patents.
Adlarity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adlarity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 11, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adlarity Generic API suppliers:
Donepezil Hydrochloride is the generic name for the brand Adlarity. 39 different companies have already filed for the generic of Adlarity, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adlarity's generic
Alternative Brands for Adlarity
Adlarity which is used for treating mild, moderate, and severe dementia of the Alzheimer's type., has several other brand drugs using the same active ingredient (Donepezil Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Eisai Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Donepezil Hydrochloride, Adlarity's active ingredient. Check the complete list of approved generic manufacturers for Adlarity
About Adlarity
Adlarity is a drug owned by Corium Llc. It is used for treating mild, moderate, and severe dementia of the Alzheimer's type. Adlarity uses Donepezil Hydrochloride as an active ingredient. Adlarity was launched by Corium in 2022.
Approval Date:
Adlarity was approved by FDA for market use on 11 March, 2022.
Active Ingredient:
Adlarity uses Donepezil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Donepezil Hydrochloride ingredient
Treatment:
Adlarity is used for treating mild, moderate, and severe dementia of the Alzheimer's type.
Dosage:
Adlarity is available in system form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/DAY | SYSTEM | Prescription | TRANSDERMAL |
| 10MG/DAY | SYSTEM | Prescription | TRANSDERMAL |